NetworkNewsBreaks – Positive Media Attention Rec
Post# of 228
(Total Views: 836)
Posted On: 06/22/2017 6:47:50 PM
NetworkNewsBreaks – Positive Media Attention Recognizes InMed Pharmaceuticals’ (IMLFF) Operational Developments, Leadership Team
Ongoing media coverage continues to recognize and highlight the achievements of InMed Pharmaceuticals, Inc. (OTCQB: IMLFF), a preclinical biopharmaceutical company focused on developing therapies through research and development into the pharmacology of cannabinoids and drug delivery systems. The company was featured as a “Cannabis Runner” by Insider Financial earlier this year, and Forbes also more recently released an article calling InMed “more than just another cannabis drug company.”
“Although the company’s pipeline is expected to generate a significant amount of attention in 2018, InMed Pharmaceuticals’ manufacturing system and database are catching the eye of investors and biotech companies. THC and CBD have, of course, been used for treating medical conditions, but there are now more than 90 different cannabinoids identified in one plant, and all of these are thought to serve various purposes. InMed has managed to plug these different cannabinoids into its system, allowing the bioinformatics compounds to test them against various illnesses and drug compounds, matching the right cannabinoids to help fight specific diseases.”
“This tool has helped the company identify two therapies, one for epidermolysis bullosa (EB), a rare skin disease found in children, and one for glaucoma, a degenerative condition that causes damage to a person’s optic nerve. In addition to all of the above, the company has now developed a method of biosynthesis similar to that used to create synthetic insulin, but for cannabinoids. This process is not only cheaper, but quicker, and it gives access to cannabinoids that are not currently profitable to turn into drugs.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Ongoing media coverage continues to recognize and highlight the achievements of InMed Pharmaceuticals, Inc. (OTCQB: IMLFF), a preclinical biopharmaceutical company focused on developing therapies through research and development into the pharmacology of cannabinoids and drug delivery systems. The company was featured as a “Cannabis Runner” by Insider Financial earlier this year, and Forbes also more recently released an article calling InMed “more than just another cannabis drug company.”
“Although the company’s pipeline is expected to generate a significant amount of attention in 2018, InMed Pharmaceuticals’ manufacturing system and database are catching the eye of investors and biotech companies. THC and CBD have, of course, been used for treating medical conditions, but there are now more than 90 different cannabinoids identified in one plant, and all of these are thought to serve various purposes. InMed has managed to plug these different cannabinoids into its system, allowing the bioinformatics compounds to test them against various illnesses and drug compounds, matching the right cannabinoids to help fight specific diseases.”
“This tool has helped the company identify two therapies, one for epidermolysis bullosa (EB), a rare skin disease found in children, and one for glaucoma, a degenerative condition that causes damage to a person’s optic nerve. In addition to all of the above, the company has now developed a method of biosynthesis similar to that used to create synthetic insulin, but for cannabinoids. This process is not only cheaper, but quicker, and it gives access to cannabinoids that are not currently profitable to turn into drugs.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)InMed Pharmaceuticals, Inc. (INM) Stock Research Links
Scroll down for more posts ▼